Free Trial
LON:N4P

N4 Pharma (N4P) Share Price, News & Analysis

N4 Pharma logo
GBX 0.68 0.00 (0.00%)
As of 05/18/2026

About N4 Pharma Stock (LON:N4P)

Key Stats

Today's Range
0.60
▼
0.75
50-Day Range
0.68
▼
0.68
52-Week Range
0.35
▼
1
Volume
1.32 million shs
Average Volume
855,053 shs
Market Capitalization
£5.66 million
P/E Ratio
N/A
Dividend Yield
3.12%
Price Target
N/A
Consensus Rating
N/A

Company Overview

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments. click here to visit our investor hub https://investors.n4pharma.com/

Receive N4P Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for N4 Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

N4P Stock News Headlines

N4 Pharma Plc Regulatory News
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
N4 Pharma PLC reports change in major holdings
N4 Pharma PLC
See More Headlines

N4P Stock Analysis - Frequently Asked Questions

N4 Pharma's stock was trading at GBX 0.50 at the beginning of 2026. Since then, N4P stock has increased by 35.2% and is now trading at GBX 0.68.

N4 Pharma Plc (LON:N4P) released its quarterly earnings results on Thursday, September, 25th. The company reported GBX (0.09) earnings per share (EPS) for the quarter. N4 Pharma had a negative trailing twelve-month return on equity of 119.30% and a negative net margin of 14,542.71%.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:N4P
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£1.63 million
Net Margins
-14,542.71%
Pretax Margin
N/A
Return on Equity
-119.30%
Return on Assets
-56.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.24
Quick Ratio
7.28

Sales & Book Value

Annual Sales
£7.07 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
2.25
Book Value
GBX 0.45 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
832,280,000
Free Float
N/A
Market Cap
£5.66 million
Optionable
Not Optionable
Beta
-0.37
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (LON:N4P) was last updated on 5/18/2026 by MarketBeat.com Staff.
From Our Partners